Literature DB >> 16678014

Iron-binding antioxidant capacity is impaired in diabetes mellitus.

Ann Van Campenhout1, Christel Van Campenhout, Albert R Lagrou, Greta Moorkens, Christophe De Block, Begoña Manuel-y-Keenoy.   

Abstract

Increased lipid peroxidation contributes to diabetic complications and redox-active iron is known to play an important role in catalyzing peroxidation reactions. We aimed to investigate if diabetes affects the capacity of plasma to protect against iron-driven lipid peroxidation and to identify underlying factors. Glycemic control, serum iron, proteins involved in iron homeostasis, plasma iron-binding antioxidant capacity in a liposomal model, and non-transferrin-bound iron were measured in 40 type 1 and 67 type 2 diabetic patients compared to 100 nondiabetic healthy control subjects. Iron-binding antioxidant capacity was significantly lower in the plasma of diabetic subjects (83 +/- 6 and 84 +/- 5% in type 1 and type 2 diabetes versus 88 +/- 6% in control subjects, p < 0.0005). The contribution of transferrin, ceruloplasmin, and albumin concentrations to the iron-binding antioxidant capacity was lost in diabetes (explaining only 4.2 and 6.3% of the variance in type 1 and type 2 diabetes versus 13.9% in control subjects). This observation could not be explained by differences in Tf glycation, lipid, or inflammatory status and was not associated with higher non-transferrin-bound iron levels. Iron-binding antioxidant capacity is decreased in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678014     DOI: 10.1016/j.freeradbiomed.2006.01.010

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  9 in total

1.  Association between Iron Intake and Progression of Knee Osteoarthritis.

Authors:  Limin Wu; Haibo Si; Yi Zeng; Yuangang Wu; Mingyang Li; Yuan Liu; Bin Shen
Journal:  Nutrients       Date:  2022-04-18       Impact factor: 6.706

Review 2.  Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring.

Authors:  Matthew Stroh; Russell H Swerdlow; Hao Zhu
Journal:  Biochem Pharmacol       Date:  2013-12-19       Impact factor: 5.858

3.  Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset.

Authors:  Thomas O Metz; Wei-Jun Qian; Jon M Jacobs; Marina A Gritsenko; Ronald J Moore; Ashoka D Polpitiya; Matthew E Monroe; David G Camp; Patricia W Mueller; Richard D Smith
Journal:  J Proteome Res       Date:  2007-12-20       Impact factor: 4.466

4.  Increased serotransferrin and ceruloplasmin turnover in diet-controlled patients with type 2 diabetes.

Authors:  Makan Golizeh; Kwangwon Lee; Serguei Ilchenko; Abdullah Ösme; James Bena; Rovshan G Sadygov; Sangeeta R Kashyap; Takhar Kasumov
Journal:  Free Radic Biol Med       Date:  2017-10-25       Impact factor: 7.376

5.  The immunobiology of apotransferrin in type 1 diabetes.

Authors:  K Mangano; P Fagone; M Di Mauro; E Ascione; V Maiello; T Milicic; A Jotic; N M Lalic; T Saksida; I Stojanovic; C Selmi; C Farina; S Stosic-Grujicic; P Meroni; F Nicoletti
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

6.  Serum albumin levels: a simple answer to a complex problem? Are we on the right track of assessing metabolic syndrome?

Authors:  Sohee Kim; Shinae Kang
Journal:  Endocrinol Metab (Seoul)       Date:  2013-03

7.  Neurotoxic effects of iron overload under high glucose concentration.

Authors:  Shi Zhao; Lin Zhang; Zihui Xu; Weiqun Chen
Journal:  Neural Regen Res       Date:  2013-12-25       Impact factor: 5.135

Review 8.  Albumin and multiple sclerosis.

Authors:  Steven M LeVine
Journal:  BMC Neurol       Date:  2016-04-12       Impact factor: 2.474

Review 9.  The (Bio)Chemistry of Non-Transferrin-Bound Iron.

Authors:  André M N Silva; Maria Rangel
Journal:  Molecules       Date:  2022-03-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.